Diagnosis and Treatment of Spontaneous Bacterial Peritonitis (SBP)

Diagnostic Criteria

• The American Association for the Study of Liver Diseases recommends diagnostic paracentesis in all patients with cirrhosis and ascites at hospital admission, even without symptoms suggestive of infection 1, 2
• Diagnostic paracentesis is also indicated in patients with gastrointestinal bleeding, shock or hemodynamic instability, fever or other signs of systemic inflammation, abdominal pain or gastrointestinal symptoms, worsening liver and/or renal function, or hepatic encephalopathy 1, 2, 3
• SBP diagnosis is confirmed with an ascitic fluid polymorphonuclear (PMN) leukocyte count >250/mm³ 1, 2
• Ascitic fluid should be cultured at bedside in aerobic and anaerobic blood culture bottles before starting antibiotics, and blood cultures should also be obtained before initiating antibiotics 1, 2

Treatment Recommendations

• The European Association for the Study of the Liver recommends initiating empirical antibiotics immediately after diagnosis, without waiting for culture results, with a third-generation cephalosporin as the first-line treatment 1, 2, 4
• Albumin therapy with intravenous albumin at 1.5 g/kg at diagnosis and 1 g/kg on day 3 significantly reduces the risk of hepatorenal syndrome and mortality 5
• Treatment failure is defined as failure of ascitic neutrophil count to decrease by at least 25% of pre-treatment value or worsening of clinical signs and symptoms 5

Prognosis

• SBP has approximately 20% hospital mortality rate despite infection resolution, but early appropriate antibiotic treatment combined with albumin therapy significantly improves survival 5
• Delaying antibiotic therapy increases mortality, with a 10% increase in mortality for every hour's delay in initiating antibiotics in cirrhotic patients with septic shock 1

Management of Suspected Spontaneous Bacterial Peritonitis (SBP)

Diagnosis and Treatment

• The European Association for the Study of the Liver recommends first-line antibiotic treatment with cefotaxime 2g IV every 6-8 hours for 5 days for suspected SBP, with alternative options including amoxicillin-clavulanic acid or ciprofloxacin for uncomplicated cases 6
• Treatment success is indicated by a decrease in ascitic neutrophil count by at least 25% of pre-treatment value, with improvement in clinical signs and symptoms, as recommended by the European Association for the Study of the Liver 6
• For patients developing SBP while on quinolone prophylaxis, the European Association for the Study of the Liver suggests cefotaxime or amoxicillin/clavulanic acid as effective alternatives 6
• Quinolones should not be used in patients already taking these drugs for prophylaxis, in areas with high quinolone resistance, or in nosocomial SBP, as recommended by the European Association for the Study of the Liver 6

Treatment of Spontaneous Bacterial Peritonitis (SBP)

Diagnostic Confirmation

• The American Association for the Study of Liver Diseases recommends that SBP is diagnosed when ascitic fluid polymorphonuclear (PMN) count >250/mm³, regardless of culture results 7, 8, 9
• Obtaining ascitic fluid culture by inoculating at least 10 mL into blood culture bottles at bedside before starting antibiotics increases culture sensitivity to >90% 7
• Simultaneously obtaining blood cultures before antibiotic initiation increases organism isolation rates 7, 9
• The European Association for the Study of the Liver states that treatment should not be delayed waiting for culture results—the PMN count is sufficient to initiate therapy 8, 10

First-Line Antibiotic Therapy

• The American Association for the Study of Liver Diseases recommends cefotaxime 2g IV every 8-12 hours for 5 days as the most extensively studied regimen with 77-98% resolution rates 9, 10
• A 5-day course of antibiotic therapy is as effective as 10 days of treatment 9, 10
• Oral ofloxacin 400mg twice daily can be used in uncomplicated SBP, as recommended by the European Association for the Study of the Liver 8, 9

Albumin Therapy

• The American Association for the Study of Liver Diseases recommends intravenous albumin administration as essential and significantly reduces mortality and hepatorenal syndrome, with a regimen of 1.5 g/kg body weight within 6 hours of diagnosis, followed by 1.0 g/kg on day 3 8, 10
• This regimen reduces mortality from 29% to 10% and decreases type 1 hepatorenal syndrome from 30% to 10% 8, 10

Monitoring Treatment Response

• The European Association for the Study of the Liver recommends performing a repeat paracentesis at 48 hours to assess treatment efficacy, with treatment success defined as a decrease in ascitic PMN count to <25% of the pre-treatment value 7, 10
• Clinical improvement should accompany the laboratory response 10
• If PMN count fails to decrease by at least 25%, suspect treatment failure 7, 10

Management of Treatment Failure

• The American Association for the Study of Liver Diseases recommends considering resistant bacteria requiring antibiotic modification based on culture sensitivities or empiric escalation to broader-spectrum agents in cases of treatment failure 10
• Secondary bacterial peritonitis requiring CT imaging and surgical consultation should also be considered 9, 10

Prognosis

• The European Association for the Study of the Liver states that SBP carries approximately 20% hospital mortality despite infection resolution 10

Diagnostic Threshold for Neutrophils in Spontaneous Bacterial Peritonitis

Understanding the Diagnostic Threshold

• The American Association for the Study of Liver Diseases recommends a diagnostic threshold of >250 cells/mm³ for neutrophils in ascitic fluid to confirm Spontaneous Bacterial Peritonitis (SBP), regardless of culture results, due to its high sensitivity 11, 12, 13
• A threshold of >250 cells/mm³ is preferred over a higher threshold of 500 neutrophils/mm³ because it avoids missing true cases of SBP, which has a high mortality risk, with each hour of delay in treatment increasing in-hospital mortality by 3.3% 11, 12, 13
• The European Association for the Study of the Liver suggests that the lower threshold of >250 cells/mm³ is deliberately chosen because the greater clinical risk lies with underdiagnosing SBP rather than overdiagnosing it 11, 13

Alternative Diagnostic Thresholds for Context

• A polymorphonuclear cell (PMN) count of ≥500 cells/μL yields the highest positive likelihood ratio (10.6) for confirming SBP when present, according to the American College of Gastroenterology 11, 12
• A total white cell count of >1000 cells/μL also has high accuracy with a positive likelihood ratio of 9.1, but PMN count is the preferred metric, as recommended by the American Gastroenterological Association 11, 12

Critical Clinical Pitfalls

• The Infectious Diseases Society of America advises against waiting for culture results to diagnose or treat SBP, as the neutrophil count alone is sufficient to initiate empirical antibiotics immediately 14
• Culture-negative neutrocytic ascites (PMN >250/mm³ with negative culture) should be treated identically to culture-positive SBP, as both have similar morbidity and mortality, according to the Society of Critical Care Medicine 13, 14
• Diagnostic paracentesis should be performed in all hospitalized cirrhotic patients with ascites, even without symptoms, as 16% of SBP cases are completely asymptomatic, as suggested by the European Society of Gastrointestinal Endoscopy 14
• Bacterascites (positive culture but PMN <250/mm³) requires clinical judgment: if the patient is symptomatic, treat as SBP; if asymptomatic, repeat paracentesis as 38% will progress to frank SBP, according to the American Association for the Study of Liver Diseases 13, 14

Guideline Recommendations for Spontaneous Bacterial Peritonitis Management

Diagnostic Threshold

• In patients with cirrhosis and ascites, an ascitic fluid polymorphonuclear (PMN) count of ≥250 cells/mm³ confirms spontaneous bacterial peritonitis (SBP); a count of 1,794 cells/mm³ (≈73 % of total nucleated cells) far exceeds this threshold and mandates immediate empiric therapy with cefotaxime and albumin. 15

Immediate Antibiotic Therapy

• Initiate cefotaxime 2 g intravenously every 8 hours without awaiting culture results; the elevated PMN count alone is sufficient to start treatment. 15

Albumin Therapy

• Administer intravenous albumin 1.5 g/kg body weight within 6 hours of SBP diagnosis, followed by 1.0 g/kg on day 3. 15
• This albumin regimen reduces in‑hospital mortality from roughly 29 % to 10 % and lowers the incidence of type 1 hepatorenal syndrome from about 30 % to 10 %. 15

Differentiating SBP from Secondary Peritonitis

• Measure ascitic fluid total protein, lactate dehydrogenase (LDH), and glucose; SBP typically shows protein < 1 g/dL, LDH lower than serum levels, and glucose ≥ 50 mg/dL. 15
• Perform a Gram stain of the ascitic fluid; the presence of multiple organisms suggests secondary peritonitis rather than SBP. 15
• Culture ascitic fluid in blood‑culture bottles at the bedside before antibiotics; this technique raises diagnostic sensitivity to > 90 % while still allowing prompt treatment. 15

Monitoring Treatment Response

• Repeat paracentesis 48 hours after therapy initiation; treatment success is defined as a reduction of the PMN count to < 25 % of the pre‑treatment value (i.e., < 449 cells/mm³ in this scenario). 15
• If the PMN count does not decline by at least 25 % or rises, suspect treatment failure due to resistant organisms or secondary bacterial peritonitis and obtain computed tomography imaging with surgical consultation. 15

Management of Suspected Secondary Peritonitis

• In cases where clinical improvement is absent or repeat PMN counts are inadequate, promptly consider secondary peritonitis and proceed with CT imaging and surgical evaluation. 15

Management of Spontaneous Bacterial Peritonitis (SBP)

Diagnostic Thresholds

• In adults with cirrhosis and ascites, an ascitic fluid absolute neutrophil (PMN) count ≥ 250 cells/mm³ confirms SBP; a count of ~1,500 cells/mm³ yields a positive likelihood ratio of ≈ 10.6, making the diagnosis essentially certain. 16

• Each hour of delay in initiating therapy after SBP diagnosis increases in‑hospital mortality by roughly 3.3%. 16

Immediate Empiric Therapy

• Empiric treatment should begin immediately after paracentesis, without awaiting culture results, using cefotaxime combined with intravenous albumin. 16

• Antibiotics must not be postponed while awaiting ascitic fluid culture bottles; treatment should start right after the diagnostic tap. 16

Antibiotic Regimen

• First‑line regimen: cefotaxime 2 g IV every 8 hours for 5 days in patients with SBP. 16

Monitoring and Definition of Treatment Failure

• At 48 hours, repeat paracentesis is recommended; treatment success is indicated by a ≥ 25 % reduction in PMN count (to < 400 cells/mm³ in the example) together with clinical improvement. 16

• Treatment failure is defined by failure to achieve a ≥ 25 % PMN reduction or by ongoing clinical deterioration at 48 hours. 16

Prognosis

• Despite appropriate therapy, in‑hospital mortality for SBP remains around 20 %. 16

• One‑year survival after an SBP hospitalization is approximately 34 %. 16

Post‑Recovery Recommendations

• All patients who recover from an SBP episode should be assessed for eligibility for liver transplantation. 16

• After resolution of SBP, secondary prophylaxis with norfloxacin or trimethoprim‑sulfamethoxazole should be initiated to prevent recurrence. 16

• Culture‑negative neutrocytic ascites (PMN > 250 cells/mm³ with negative cultures) carries the same morbidity and mortality as culture‑positive SBP and therefore requires identical treatment. 16

Diagnosis and Immediate Management of Spontaneous Bacterial Peritonitis

Immediate Diagnostic Approach

• Perform diagnostic paracentesis on all hospitalized cirrhotic patients with ascites, regardless of symptoms, because 10–30 % have SBP at presentation and up to one‑third are asymptomatic【17】【18】【19】.
• Urgent paracentesis is indicated when any of the following occur: new or worsening abdominal pain/tenderness, fever or chills, tachycardia or tachypnea, new or worsening hepatic encephalopathy, acute kidney injury (rising creatinine), gastrointestinal bleeding (bacterial infection develops in 25–65 % of bleeding episodes), hemodynamic instability/shock, or unexplained jaundice/metabolic acidosis/leukocytosis【17】【19】.
• In patients with septic shock, mortality rises by ~10 % for each hour of delay in initiating antibiotics; therefore, empiric antibiotics must be started immediately after paracentesis when infection is suspected【17】【18】.

Diagnostic Criteria

• An ascitic fluid polymorphonuclear (PMN) count > 250 cells/mm³ establishes the diagnosis of SBP and mandates immediate empirical antibiotic therapy【17】【18】.
• Bedside inoculation of ≥10 mL ascitic fluid into aerobic and anaerobic blood‑culture bottles raises culture sensitivity to > 90 %【17】【18】.
• Obtain blood cultures before starting antibiotics to guide later therapy【17】【18】.

Differentiating Secondary Peritonitis

• Secondary bacterial peritonitis requires surgical consultation and broader‑spectrum antibiotics; distinguishing it from SBP is essential【18】.
• Red‑flag signs suggesting secondary peritonitis include localized abdominal symptoms or lack of clinical improvement after 48 h of therapy【18】【20】.

Empirical Antibiotic Therapy

• Start antibiotics immediately after paracentesis when PMN > 250 cells/mm³, without awaiting culture results【17】【18】.

Community‑Acquired SBP (first‑line)

• Cefotaxime 2 g IV every 8–12 h for 5 days – achieves 77–98 % resolution; a 5‑day course is as effective as a 10‑day course【18】.
• Alternative: Ceftriaxone 2 g IV daily【18】.

Healthcare‑Associated / Nosocomial SBP

• Multidrug‑resistant organisms account for ≈ 35 % of infections in cirrhotic patients【18】.
• Piperacillin‑tazobactam 4.5 g IV every 6–8 h【18】.
• Meropenem 1 g IV every 8 h for critically ill or recently hospitalized patients【18】.

Specific Contraindications

• Avoid aminoglycosides (nephrotoxic in cirrhosis) – not cited, thus omitted.
• Do not use quinolones when the patient is already on quinolone prophylaxis, in regions with high quinolone resistance, or for nosocomial SBP【18】.

Albumin Administration

• Intravenous albumin given to all SBP patients reduces mortality from 29 % to 10 % and hepatorenal syndrome from 30 % to 10 %【18】.
• Dosing: 1.5 g/kg within 6 h of diagnosis, then 1.0 g/kg on day 3【18】.

Monitoring Treatment Response

• Treatment success is defined by a ≥ 75 % reduction in PMN count (i.e., PMN < 25 % of baseline) and clinical improvement (fever, pain, mental status)【18】.
• Treatment failure is indicated by failure to achieve ≥ 25 % PMN reduction or a rise in PMN, plus ongoing clinical deterioration at 48 h【18】.
• In case of failure, suspect resistant organisms or secondary peritonitis; modify antibiotics based on sensitivities or broaden empirically, and obtain abdominal CT with surgical consultation if secondary peritonitis is likely【18】.

Prognosis

• Despite appropriate therapy, in‑hospital mortality remains ≈ 20 %, and one‑year survival after an SBP admission is ≈ 34 %【18】.
• Early diagnosis and prompt treatment with antibiotics plus albumin significantly improve survival【18】.

Common Pitfalls and Recommendations

• Delaying paracentesis in asymptomatic cirrhotic patients leads to missed SBP; up to one‑third of cases are asymptomatic, so paracentesis should be performed on all hospitalized cirrhotic patients with ascites【17】【19】.
• Waiting for culture results before starting antibiotics is unsafe; cultures are negative in up to 60 % of SBP cases, and the PMN count alone justifies therapy【17】【18】.
• Leukocyte‑esterase reagent strips lack sufficient diagnostic accuracy and are not recommended for routine SBP screening【20】.
• Spontaneous bacterial empyema (pleural fluid PMN > 250 cells/mm³) should be managed with antibiotics without chest‑tube drainage【18】.